[Form 4] Cardiff Oncology, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cardiff Oncology Chief Operating Officer Ajay Aggarwal received a grant of stock options covering 400,000 shares of common stock. The options have an exercise price of $1.72 per share and expire on April 27, 2036, giving him a long-term incentive tied to the company’s share price.
According to the vesting schedule, 100,000 options vest on April 27, 2027, and 8,333 options vest monthly for 36 months beginning on May 27, 2027. After this grant, Aggarwal holds 400,000 stock options directly under this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Aggarwal Ajay
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 400,000 | $0.00 | -- |
Holdings After Transaction:
Stock Options — 400,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 400,000 options
Exercise price: $1.72 per share
Options expiration: April 27, 2036
+3 more
6 metrics
Stock options granted
400,000 options
Grant to COO Ajay Aggarwal on April 27, 2026
Exercise price
$1.72 per share
Exercise price for the 400,000 stock options
Options expiration
April 27, 2036
Expiration date of the stock option award
Initial cliff vest
100,000 options
Vest on April 27, 2027
Monthly vesting tranche
8,333 options per month
Vest monthly for 36 months starting May 27, 2027
Total options after grant
400,000 options
Total stock options held under this grant following transaction
Key Terms
Stock Options, exercise price, vesting, Common Stock
4 terms
Stock Options financial
"security_title: "Stock Options""
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"conversion_or_exercise_price: "1.7200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100,000 vest on April 27, 2027 and 8,333 vest monthly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What did Cardiff Oncology (CRDF) disclose about Ajay Aggarwal in this Form 4?
Cardiff Oncology reported that COO Ajay Aggarwal received a grant of 400,000 stock options. These options are compensation-based awards that allow him to buy company common stock at a fixed $1.72 exercise price in the future if he chooses.
How many stock options did Cardiff Oncology (CRDF) grant to its COO?
Ajay Aggarwal was granted 400,000 stock options tied to Cardiff Oncology common stock. This entire award is held directly and represents a derivative position that can become shares if he exercises the options after they vest over time.
What is the exercise price of Ajay Aggarwal’s Cardiff Oncology (CRDF) options?
The stock options granted to Ajay Aggarwal have an exercise price of $1.72 per share. This means he can later purchase Cardiff Oncology common stock at $1.72 for each option that has vested and remains unexpired, regardless of future market prices.
When do Ajay Aggarwal’s Cardiff Oncology (CRDF) stock options vest?
The options vest in stages: 100,000 options vest on April 27, 2027, and 8,333 options vest monthly for 36 months starting May 27, 2027. This creates a multi-year vesting schedule that encourages long-term alignment with the company.
When do the Cardiff Oncology (CRDF) stock options granted to the COO expire?
Ajay Aggarwal’s stock options expire on April 27, 2036. After that date, any unexercised options will lapse. The long duration gives him many years in which vested options can potentially be exercised, depending on company performance and his decisions.